Access Denied

Heading to #ObesityWeek? Connect with ICON experts at booth \#212 to explore how our cross-functional obesity expertise and integrated scientific and operational support can help navigate the complexities of obesity deve...

Healthcare decisions depend on evidence that is relevant, rigorous and meaningful. At #ISPOREurope2026, ICON and Mapi Research Trust will be sharing research across multiple poster sessions, covering clinical outcome ass...

Biopsies remain the gold standard in MASH clinical trials, but they are far less common in everyday clinical practice. As more patients are diagnosed and managed using non-invasive tests, the gap between routine care a...

Could streamlined regulatory pathways reduce the need for comparative efficacy studies in some biosimilar programmes? In this BioProcess International article, authors Kimberly Salgado & Radboud van Trigt discuss how re...

Meet scientific publication security and compliance with increased confidence. PubsHub PMSolution features audit trail support for GPP2022 and ICMJE guidelines to meet best practices. You can place more focus on the work...

As clinical development becomes more complex and data-driven, operating models need to evolve to support faster, more confident decision-making. This latest blog explores how FSP, FSO and hybrid approaches can be aligned...

As oncology programs become increasingly complex, medical imaging plays a critical role in development success. ICON Medical Imaging combines scientific leadership, strategic insight and integrated solutions to support s...

Global AI regulation is becoming more complex, not less. From FDA guidance and PCCPs to the EU AI Act, UK reforms and emerging APAC frameworks, manufacturers must navigate multiple approaches to risk classification, lif...

Connect with ICON’s hepatology experts at AASLD, booth \#1861, to explore how we can support your liver disease trials, from smarter site selection powered by AI and expert insight to imaging, biomarkers and endpoint str...

Rare disease studies demand flexibility. Digital solutions and decentralised models can help reduce patient burden, improve access and support participation. Meet the ICON team at #WorldOrphanEU, booth \#313, to discuss ...

Drop by booth \#69 at #OCTNewEngland2026, 27– 28 October. Meet the ICON team to explore new solutions to common issues within clinical trials. Learn how we can simplify processes to help you meet critical milestones, on ...

Approval is not access. EMA marketing authorisation does not guarantee a positive reimbursement outcome. Under JCA, sponsors must show relative clinical effectiveness and safety through evidence that reflects European p...